MIMEDX GROUP - Key Persons

Job Titles:

• Audit Committee

Dr. Laurencin currently serves the Albert and Wilda Van Dusen Distinguished Endowed Professor of Orthopaedic Surgery at the University of Connecticut, and is one of two designated University Professors at the school. He is also a materials scientist and engineer and is Professor of Materials Science and Engineering, Professor of Chemical and Biomolecular Engineering, and Professor of Biomedical Engineering at the University of Connecticut. He has been a professor at the University of Connecticut since 2008. He is the Chief Executive Officer of The Connecticut Convergence Institute for Translation in Regenerative Engineering. Previously, he served as Vice President for Health Affairs at the University of Connecticut Health Center and Dean of the University of Connecticut School of Medicine. From 2003 until 2008, Dr. Laurencin was the Lillian T. Pratt Distinguished Professor and Chair of the Department of Orthopedic Surgery at the University of Virginia. Dr. Laurencin was also designated a University Professor by the President of the University of Virginia. Prior to 2003, Dr. Laurencin held various positions of increasing responsibility at Drexel University, including the Helen I. Moorehead Distinguished Professor of Chemical Engineering, Vice Chairman of the Department of Orthopedic Surgery and Director of Shoulder Surgery, and at MCP-Hahnemann School of Medicine, where he served as Clinical Professor of Orthopedic Surgery and Research Professor of Pharmacology and Physiology. An International Fellow in Biomaterials Science and Engineering, he received the Founders Award from the Society for Biomaterials. He is an elected member of the National Academy of Medicine, the National Academy of Engineering, and the American Academy of Arts and Sciences. Dr. Laurencin is the recipient of the National Medal of Technology and Innovation, our nation's highest honor for technological achievement. He has over 500 publications and patents. Dr. Laurencin received his B.S.E. degree in engineering from Princeton University, his Ph.D. in biochemical engineering and biotechnology from the Massachusetts Institute of Technology, and his M.D. from the Harvard Medical School. Dr. Laurencin is NACD Directorship Certified®. He was nominated to serve as a director because of his experience as a practitioner and professor of orthopaedic surgery, as well as his deep technical, research, and clinical experience.

Job Titles:

• Certified Public Accountant
• Chief Financial Officer

Mr. Rice joined MIMEDX in July 2023 as the Company's Chief Financial Officer. He brings more than a decade of experience in the MedTech industry having served in several executive leadership positions throughout his career. Most recently, he served as the CFO of Orthofix Medical, a leading global spine and orthopedics company. Prior to Orthofix, Mr. Rice was CFO at Vision Source, held several finance leadership roles at both McAfee and Concentra, and started his career at PricewaterhouseCoopers. Mr. Rice is a Certified Public Accountant and received his BBA with honors and his MBA from Southern Methodist University.

Job Titles:

• Chairman of the Board
• Member of the Audit Committee
• Audit Committee
• Independent Life Sciences Consultant and Investor

Dr. M. Kathleen Behrens served as a member of the board of directors of each of Sarepta Therapeutics, Inc. (SRPT), a multi-billion dollar medical research and drug development company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, since March 2009 (Chairwoman of the Board since April 2015) and IGM Biosciences, Inc., a privately held biotechnology company, since January 2019. Dr. Behrens has worked as an independent life sciences consultant and investor since December 2009. She served as the Co-Founder, President, Chief Executive Officer and as a director of the KEW Group Inc., a private oncology services company, from January 2012 until June 2014. Earlier in her career, Dr. Behrens served as a general partner for selected venture funds for RS Investments, a mutual fund firm, from 1996 until December 2009. While Dr. Behrens worked at RS Investments, from 1996 to 2002, she served as a managing director at the firm and, from 2003 to December 2009, she served as a consultant to the firm. During that time, Dr. Behrens also served as a member of the President's Council of Advisors on Science and Technology (PCAST), from 2001 to 2009 and as chairwoman of PCAST's Subcommittee on Personalized Medicine, as well as the President, director and chairwoman of the National Venture Capital Association, an organization that advocates for public policy that supports the American Entrepreneurial ecosystem, from 1993 until 2000. Prior to that, she served as a general partner and managing director for Robertson Stephens & Co., an investment company, from 1983 through 1996. She served as a director of Amylin Pharmaceuticals, Inc. (formerly AMLN), a biopharmaceutical company, from 2009 until the company's sale in 2012 to Bristol-Myers Squibb Co. Prior to that, she served on the board of directors Abgenix, Inc. (formerly ABGX), a biopharmaceutical company, from 2001 until the company was sold to Amgen, Inc. in 2006. From 1997 to 2005, Dr. Behrens was a director of the Board on Science, Technology and Economic Policy for the National Research Council. Dr. Behrens was also a Co-Founder of the Coalition for 21st Century Medicine, a trade association for new generation diagnostics companies. Dr. Behrens holds a B.S. in Biology and a Ph.D. in Microbiology from the University of California, Davis.

Job Titles:

• SVP, Marketing & International

Mr. Smith joined MIMEDX in 2021 and currently serves as the Senior Vice President of Marketing & International. Prior to MIMEDX, Mr. Smith was the Chief Commercial Officer at Ascensus Surgical (formerly known as TransEnterix), a global provider of abdominal robotics and augmented reality systems. Prior thereto, he was the Vice President and Global Acute Franchise Leader at Acelity (formerly known as KCI) responsible for all wound care products sold in the hospital setting. He has over 25 years of experience in the health care sector and has held executive level roles at Johnson & Johnson, Boston Scientific and Signet Laboratories. Mr. Smith holds a B.S. in Business Administration from the University of New Hampshire and an MBA from Babson College.

Job Titles:

• Member of the Audit Committee
• Audit Committee

Mr. Bierman served as President and Chief Executive Officer of Owens & Minor, Inc., a Fortune 500 company and a leading distributor of medical and surgical supplies, from September 2014 to June 2015. Previously, he served in various other senior roles at Owens & Minor, including President and Chief Operating Officer from August 2013 to September 2014, Executive Vice President and Chief Operating Officer from March 2012 to August 2013, Executive Vice President and Chief Financial Officer from April 2011 to March 2012, and Senior Vice President and Chief Financial Officer from June 2007 to April 2011. Earlier in his career, Mr. Bierman served as Executive Vice President and Chief Financial Officer at Quintiles Transnational Corp. Prior to joining Quintiles Transnational, Mr. Bierman was a partner at Arthur Andersen LLP for over a decade. Mr. Bierman currently serves on the board of directors of Tenet Healthcare Corporation (THC) and Novan, Inc. Mr. Bierman previously served on the boards of directors of Owens & Minor, Inc. (OMI) and Team Health Holdings, Inc. (formerly TMH). Mr. Bierman earned his B.A. from Dickinson College and his M.B.A. at Cornell University's Johnson Graduate School of Management. Mr. Bierman joined our board in June 2019 as part of our board refreshment process. In addition to his leadership, Mr. Bierman brings a wealth of experience in financial and operational strategies, mergers and acquisitions, and a health care industry perspective.

Job Titles:

• Chief Scientific Officer and SVP, Research and Product Development
• Chief Technology Officer and Senior Vice President of Research

Dr. Harper joined MIMEDX as Chief Technology Officer and Senior Vice President of Research and Product Development in June 2021. Most recently, he served as a Senior Medical Scientist in the Medical Solutions Division of 3M Health Care and Chief Technology Officer for 3M affiliate KCI, where he was responsible for all early-stage research, innovation and technology development and the study of mechanism of action of the company's negative pressure wound care technology. During his tenure at KCI, Dr. Harper also led the company's Clinical Development and Regulatory Affairs organization. Prior to KCI, he served as Vice President of Clinical Development and Clinical Sciences at the biotechnology company LifeCell Corporation, the previous Regenerative Medicine division of Acelity and the leader in acellular scaffold technology and makers of AlloDerm, Strattice, and GraftJacket Regenerative and Reconstructive Tissue Matrices. Dr. Harper has over 40 peer-reviewed publications and book chapters and his principal areas of research interest are extracellular matrix biochemistry, tissue regeneration, and wound healing. He currently serves as a member of the Board of Directors at Kent Imaging, Nanomedic Technologies, and American College of Wound Healing and Tissue Repair. He received his Ph.D. in Biomedical Sciences from The University of Texas, M.D. Anderson Cancer Center in Houston and completed post-doctoral fellowships in cancer biochemistry and cell biology at Scripps Clinic in La Jolla, California and the National Cancer Institute in Bethesda, Maryland.

Job Titles:

• Chief Executive Officer
• Director

Mr. Capper joined MIMEDX in January 2023 to lead the Company as Chief Executive Officer and Director. A highly experienced and accomplished healthcare executive, he brings nearly 30 years of experience in MedTech and Life Sciences leadership roles along with a track record of substantial value creation. Mr. Capper has successfully led several organizations, most recently serving as the CEO of BioTelemetry, guiding the company through a significant turn-around, which culminated with its acquisition by Royal Philips for $2.8 billion. Prior to BioTelemetry, he served as President and CEO of both Home Diagnostics and CCS Medical. Mr. Capper brings with him a wealth of commercial experience, having held several leadership roles earlier in his career during the decade he spent with Bayer AG. Additionally, he was an officer in the U.S. Navy serving with distinction as a naval aviator. Mr. Capper received his undergraduate degree in Accounting from West Chester University and MBA in

Job Titles:

• Member of the Audit Committee
• Compensation Committee

Mr. Newton joined MIMEDX's Board in 2019, and has since served as Chair of the Audit Committee and as a member of the Ethics and Compliance Committee. Mr. Newton previously served as Chief Executive Officer and as a member of the Board of Directors of Apollo Endosurgery, Inc. (Nasdaq: APEN), a medical device company, from July 2014 until March 2021. Earlier in his career, Mr. Newton served as Executive Vice President, Chief Financial Officer and Chief Operating Officer at ArthroCare Corporation (formerly Nasdaq: ARTC), a medical device company, from 2009 to June 2014. Prior to that, Mr. Newton served in a number of executive officer roles, including President and Chief Executive Officer and as a director, at Synenco Energy, Inc., a Canadian oil sands company, from 2004 until 2008. Mr. Newton was a Partner at Deloitte & Touche LLP, a professional services network and accounting organization, from 1994 to 2004. Mr. Newton holds a B.B.A. in accounting from the University of Texas at San Antonio.

Job Titles:

• Chief Human Resources Officer

A proven HR executive, Ms. Surdez brings more than 20 years of experience in Human Resources, having led talent acquisition, total rewards, succession and workforce planning, performance coaching, and organizational change management for several successful IPOs and large multinational biotech companies. She has held a variety of HR roles with increasing responsibility, most recently as the Head of HR for Vaxxinity, a clinical-stage biotech at which she built the HR function from the ground up. Prior thereto, she served as Senior Vice President of HR for Viela Bio, a successful biotech start-up spun out of AstraZeneca that was later acquired by Horizon Therapeutics. Earlier in her career, she provided HR support to multiple functions within the biologics and small molecule teams at MedImmune/AstraZeneca. Ms. Surdez holds a B.A. in History from the University of North Carolina at Wilmington.

Job Titles:

• SVP, Sales

Ms. Moller joined MIMEDX in August 2020 and brings significant sales leadership experience, clinical knowledge and understanding of the Advanced Wound Care marketplace to her role as Senior Vice President of Sales. With more than 25 years of experience in sales roles with increasing responsibility, Ms. Moller has managed national sales teams and executed on strategic growth initiatives for leading healthcare companies, including 3M and its subsidiaries Acelity and KCI. Ms. Moller holds a B.S. in Nursing (BSN) from University of Phoenix and an MBA from Colorado Christian University.

Job Titles:

• Co - Founder
• Member of the Audit Committee
• Compensation Committee

Since 1985, Mr. Sutter has been the Co-Founder and a Managing Director of EW Healthcare Partners, previously known as Essex Woodlands Health Ventures, a healthcare-focused growth equity firm. Mr. Sutter has been directly involved with more than 30 of EW Healthcare Partners' portfolio company investments. Educated in chemical engineering and finance, Mr. Sutter has more than 35 years of management experience in operations, marketing, finance and venture capital. Mr. Sutter holds a Bachelor of Science degree from Louisiana State University and a Master of Business Administration from the University of Houston. He currently serves on the Boards of Abiomed, Inc. (NASDAQ: ABMD), Bioventus LLC and Prolacta Bioscience. He previously served on the boards of directors of the following EW Healthcare Partners' portfolio investments: ATS Medical (later acquired by Medtronic, Inc.); BioForm Medical (later acquired by Merz GmbH & Co KGaA); LifeCell (later acquired by Kinetic Concepts); St. Francis Medical (later acquired by Kyphon, Inc./Medtronic, Inc.); Confluent Surgical (later acquired by Tyco International/Covidien); and Rinat Neurosciences (later acquired by Pfizer, Inc.). We believe that Mr. Sutter's in-depth knowledge of the medical device industry, his skills as an investor in developing medical device companies, his extensive board experience and his position as a representative of a large stockholder in our Company qualify him to serve as a member of our Board of Directors.

Job Titles:

• Head of Investor Relations

Job Titles:

• Consultant
• Member of the Audit Committee
• Compensation Committee

Since July 2016, Dr. Giuliani has been a consultant for several small pharmaceutical companies and has provided expert testimony for Mallinckrodt Pharmaceuticals. In addition to advising these companies, he volunteers his time and expertise to assist individuals or entities attempting to bring a pharmaceutical product forward from the pre-concept phase. From November 2007 to June 2016, Dr. Giuliani served as Vice President, Research and Development, for Mallinckrodt plc (formerly known as the Pharmaceuticals Division of Covidien) (NYSE: MNK), a developer, manufacturer, and distributor of specialty pharmaceutical products and therapies for autoimmune and rare diseases in the areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care. During his tenure, the Company obtained FDA approval for 16 new products. Prior to joining Covidien, he served as the Chief Medical Officer and Executive Vice President of Xanodyne Pharmaceuticals, an integrated specialty pharmaceutical company focused on women's healthcare and pain management. Dr. Giuliani received his B.S. from Tulane University and his M.D. from Ohio State University. Dr. Giuliani was nominated to serve as a director because of his extensive clinical and regulatory experience with multiple FDA divisions, and development, regulatory and manufacturing experience for complex biologic products.

Job Titles:

• Member of the Audit Committee
• Nominating & Corporate Governance Committee

Dr. Gardner has spent more than 35 years in academia, medicine and industry. She has served on the board of directors of several public and private companies, including Revance Therapeutics, Inc. since 2006, Corium International, Inc. from November 2007 to December 2018, and CohBar, Inc. from February 2019 to present. Dr. Gardner has also served as an advisor to Change Health Care, Inc. from April 2019 to present. From June 1999 to July 2014, she served in various capacities including as an Adjunct Partner at Essex Woodlands Health Ventures, a growth equity firm that focuses on the healthcare industry (and a predecessor firm to EW Healthcare Partners, a holder of MiMedx Series B Preferred Stock). Additionally, Dr. Gardner has been a member of the Harvard Medical School Board of Fellows since April 2013 and is a scientific reviewer for the Cancer Prevention and Research Institute of Texas. She began her academic medical career at Stanford University, where she has held several positions including Senior Associate Dean for Education and Student Affairs and remains today as Professor of Medicine. From 1994 to 1998, she took a leave of absence from Stanford University to serve as Principal Scientist, Vice President of Research and Head of ALZA Technology Institute, a major drug delivery company. Dr. Gardner earned a Bachelor of Science degree in Biology from the University of Illinois and a Doctor of Medicine degree from Harvard Medical School. She trained in Internal Medicine at Massachusetts General Hospital, followed by Chief Residency at Stanford University Hospital and post-doctoral fellowships at Columbia University and University College London.

Job Titles:

• Chief Operating Officer

Ms. Whitlow joined MIMEDX in January 2023 as Chief Operating Officer. With a demonstrated background in operational leadership, Ms. Whitlow brings to her role more than 30 years of Life Sciences and Pharmaceutical experience. She has held a variety of senior executive roles, most recently as President, Clinical Supply Services at Catalent Pharma Solutions. Prior to her role at Catalent, Ms. Whitlow's extensive career has included leadership positions at a number of MedTech and Pharmaceutical companies, including Optinose, LifeCell, Kinetic Concepts, and Johnson & Johnson. Ms. Whitlow holds a B.S. in Industrial Engineering from Texas A&M University and an MBA from the NYU/LSE/HEC TRIUM program.

Job Titles:

• Member of the Audit Committee
• Senior Advisor to EW Healthcare Partners

Mr. Hawkins serves as a Senior Advisor to EW Healthcare Partners, a life sciences private equity firm. Mr. Hawkins is the former Chairman and CEO of Medtronic, Inc., a global leader in medical technology. He was at Medtronic from 2002 until 2011. After retiring from Medtronic, he served as President and Chief Executive Officer of Immucor, Inc., a private equity backed global leader in transfusion and transplant medicine from October 2011 to July 2015. From 1998 to 2001 Mr. Hawkins served as President and Chief Executive Officer of Novoste Corporation (NASDAQ:NOVST), an interventional cardiology company. Prior to that, Mr. Hawkins served in a variety of senior roles at American Home Products, a consumer, pharma and medical device company, Johnson & Johnson, a healthcare company, Guidant Corporation, a medical products company, and Eli Lilly and Company, a global pharmaceutical company. Mr. Hawkins also serves as a director of Biogen Inc. (NASDAQ: BIIB), a biopharmaceutical company; Avanos Medical, Inc. (NYSE:AVNS), a medical technology company; as Chairman of Bioventus, LLC; as Chairman of 4 Tech; and as a director of AskBio, Cirtec, Virtue Labs, Immucor, Inc., Cereius, Inc. and Baebies, Inc., all of which are life science companies. He previously served on the board of Thoratec Corporation. Mr. Hawkins is Vice Chair of the Duke University Board of Trustees and is Chair of the Duke University Health System. Mr. Hawkins was elected as a member of the AIMBE College of Fellows and the National Academy of Engineering. He has a dual B.S.E.E. degree in Electrical and Biomedical Engineering from Duke University and a M.B.A. from the University of Virginia's Darden School of Business. Mr. Hawkins has significant leadership experience as a chief executive officer, significant knowledge of, and experience in, the healthcare industry and significant international experience. He also has extensive governance and public company board experience.

Job Titles:

• General Counsel and Chief Administrative and Compliance Officer

Mr. Hulse joined MIMEDX in December 2019, and brings to MIMEDX more than twenty years' experience in large law firms and life sciences organizations, with significant legal, risk management, compliance and operational expertise. Prior to joining the Company, Mr. Hulse was a member of Dykema, a national law firm, since 2017. Prior thereto, he was with Acelity, LP, Inc. (formerly Kinetic Concepts, Inc.) from 2008-2017 in a variety of roles of increasing responsibility. In his last role with Acelity, he served as Chief Compliance Officer and Senior Vice President for Enterprise Risk Management, Quality, and Regulatory. Prior to that, he served as Division General Counsel and Associate General Counsel for litigation matters. Mr. Hulse holds a Bachelor of Arts from Angelo State University and a Juris Doctorate from the Baylor University School of Law.